IPSC beat EPS expectations by 19.04%
Nov 08, 2024, 11:33 PM
0.00%
What does IPSC do
Century Therapeutics, based in Philadelphia, develops off-the-shelf allogeneic cell therapies for cancer, employing 152 staff since its IPO on June 17, 2021. Its product candidates target various malignancies, including CNTY-101 and CNTY-102 for B-cell lymphoma.
Century Therapeutics (IPSC) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Century Therapeutics's actual EPS was -$0.37, beating the estimate of -$0.46 per share, resulting in a 19.04% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.